Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NNC0519-0130 in healthy volunteers, overweight/obesity, and type 2 diabetes
NCT05363774Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Apr 2022
- Primary completion
- Apr 2024
- Modality
- Small Molecules, Modified Peptides, Native Peptides
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of NNC0519-0130 in type 2 diabetes mellitus (T2DM) and obesity (4 arms), sponsored by Novo Nordisk. Primary endpoint: Treatment Emergent Adverse Events at 112 days. Started Apr 2022; status: completed.
02
Drugs
NNC0519-0130
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT05363774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05363774.